Nasdaq
$0.8344▼ 0.01%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $83.5MShares out 100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 4d agoAfter-hours26.10.21 05:156-KKey event#●●●#●●●#●●●
Nyxoah SA
Nyxoah reported preliminary Q3 2026 global net revenue of €9.2 million, showing sequential growth, but lowered its full-year 2026 revenue guidance to a range of €33 million to €35 million from the previous €36 million to €40 million. The company also submitted a PMA supplement to the FDA to expand Genio's U.S. indication and reported cash and financial assets of approximately €77.0 million as of September 30, 2026.…more
$0.8344-0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29After-hours26.09.30 05:056-KKey event
Nyxoah SA
Nyxoah SA has appointed Liam Kelly as its new Chief Executive Officer, effective October 1, 2026, to accelerate the company's U.S. commercial traction. He succeeds Olivier Taelman and will lead the company's strategic evolution into a U.S.-focused commercial organization.…more
$0.8344-0.01%vs prev closeView filingShare - 9.22After-hours26.09.23 05:056-KKey event
Nyxoah SA
Nyxoah SA announced that Chief Financial Officer John Landry will step down effective October 2, 2026, and will be succeeded by Loic Moreau, the current President International, as Interim CFO. The company also reaffirmed its full-year 2026 financial guidance, including expected net revenue in the range of 36 million to 40 million euros.…more
$0.8344-0.01%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:00#●●●#●●●#●●●
Nyxoah Reports Q3 Revenue Growth but Lowers Full-Year Guidance
Nyxoah reported a 29% sequential revenue growth in the U.S. for the third quarter, yet it adjusted its full-year 2026 revenue guidance downward. While growth momentum continues, the lowered annual outlook leads to a neutral investment outlook.…more
$0.8344-0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.15After-hours26.10.16 05:08
●●●●●●●● ●●●●● ●●●●●●
Nyxoah has submitted an FDA application to expand the indication for its Genio sleep apnea treatment device. Pivotal clinical data demonstrated a 74.3% median reduction in apnea events.…more
$0.8344-0.01%vs prev closeShareBenzinga - 9.28After-hours26.09.29 05:31
●●●●●●●● ●●●●● ●●●●●●
Nyxoah has announced the appointment of Liam Kelly as its new CEO, effective October 1, 2026. Current CEO Oliver Taelman will step down from his position on that date.…more
$0.8344-0.01%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report